Skip to main content
. 2022 Jan 16;13(2):2336–2345. doi: 10.1080/21655979.2021.2018387

Figure 5.

Figure 5.

Silencing of NEAT1 inhibits inflammation and apoptosis by targeting miR-200c-3p/TRAF6 axis. (a) TRAF6 expression in healthy control individuals and CP tissues. **P < 0.01 vs. healthy control. (b) TRAF6 expression in control and model groups. **P< 0.01 vs. control. (c) The expression of TRAF6 was determined by Western blot after transfection of sh-NEAT1/sh-NEAT1 + miR-200c-3p inhibitor. **P < 0.01 vs. sh-NC. ##P < 0.01, vs. sh-NEAT1. (d-g) Cell viability and the levels of IL-6, IL-1β, and TNF-α in model + sh-NC, model + sh-NEAT1, model + sh-NEAT1 + miR-200c-3p inhibitor, and model + sh-NEAT1 + pcDNA-TRAF6 groups. **P < 0.01 vs. sh-NC. ##P < 0.01, vs. sh-NEAT1. (h-i) Relative protein expression of Bax and Bcl-2, and the ratio of Bax/Bcl-2 in Model + sh-NC, model + sh-NEAT1, model + sh-NEAT1 + miR-200c-3p inhibitor, and model + sh-NEAT1 + pcDNA-TRAF6 groups. **P < 0.01 vs. sh-NC. ##P < 0.01, vs. sh-NEAT1.